Meta-analysis Of Dedicated Renal Outcome Trials Assessing the Cardio-renal Efficacy of Sodium-Glucose Co-transporter-2 Inhibitors In Patients With Chronic Kidney Disease And Albuminuria

Chronic kidney disease (CKD) represents a frequent co-morbidity of type 2 diabetes mellitus (T2DM), affecting 30-50% of all patients, while diabetes is the leading cause of end-stage kidney disease (ESKD) worldwide.1,2 Vice versa, incidence rates of T2DM among patients with CKD are significantly higher compared to the general population.3 Sufficient glycemic control is required for all patients suffering from CKD and TDM; however, very strict control has been shown to increase all-cause mortality similarly to insufficient control.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research

Related Links:

ConclusionsMetformin use is connected with significantly less risks of all-cause mortality and cardiovascular events in patients with T2DM and mild/moderate CKD. However, RCTs with large sample sizes are warranted in the future to assess whether these key benefits extend to later stages of CKD by dose adjustment.
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
AbstractDiabetic kidney disease (DKD) occurs in approximately 20 –40% of patients with type 2 diabetes mellitus. Patients with DKD have a higher risk of cardiovascular and all-cause mortality. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and antihyperglycemic drugs form the mainstay of DKD management and aim to restrict progression to more severe stages of DKD. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) control hyperglycemia by blocking renal glucose reabsorption in addition to preventing inflammation, thereby improving endothelial function and reducing oxidative stress; consequen...
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
Conclusion: Addition of eplerenone to ACEI shows an added antialbuminuric effect without significant change of the serum K level compared with eplerenone or ACEI.Cardiorenal Med
Source: Cardiorenal Medicine - Category: Urology & Nephrology Source Type: research
Conclusion: Our results suggest that FABP1 and FABP2 may be novel biomarkers of diabetic nephropathy. PMID: 32922199 [PubMed - in process]
Source: International Journal of Medical Sciences - Category: Biomedical Science Tags: Int J Med Sci Source Type: research
AbstractAccumulating evidence has shown that patients with lifestyle diseases such as type 2 diabetes mellitus, chronic kidney disease, and chronic obstructive pulmonary disease are at increased risk of osteoporotic fracture. Fractures deteriorate quality of life, activities of daily living, and mortality as well as a lifestyle disease. Therefore, preventing fracture is an important issue for those patients. Although the mechanism of the lifestyle diseases-induced bone fragility is still unclear, not only bone mineral density (BMD) reduction but also bone quality deterioration are involved in it. Because fracture predictiv...
Source: Journal of Bone and Mineral Metabolism - Category: Orthopaedics Source Type: research
Authors: Lautsch D, Iglay K, Yang L, Bansal N, Markan R, Kathe N, Rajpathak S Abstract Objective: To assess the level of glycemic control among type 2 diabetes patients on sodium-glucose cotransporter 2 inhibitor (SGLT2i) and metformin dual therapy.Methods: Observational, retrospective database study in adult type 2 diabetes mellitus patients from the IQVIA Electronic Medical Record (EMR) database was conducted. Observation period was June 2015 to June 2018. Patient's earliest encounter in the observation period while on SGLT2i and metformin dual therapy served as the index date. Patients were required to have at l...
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
Conclusion: MicroRNA-451 is a promising early biomarker for chronic kidney disease in diabetic nephropathy with high sensitivity and specificity. PMID: 32855824 [PubMed]
Source: International Journal of Nephrology - Category: Urology & Nephrology Tags: Int J Nephrol Source Type: research
Authors: Sydorchuk L, Dzhuryak V, Sydorchuk A, Levytska S, Petrynych V, Knut R, Kshanovska A, Iftoda O, Tkachuk O, Kyfiak P, Popovich A, Khomko O, Sydorchuk R Abstract OBJECTIVE: The cytochrome 11B2 aldosterone synthase gene (CYP11B2) that links to aldosterone synthase enzyme synthesis changes and blood pressure regulation is of particular interest among the renin-angiotensin-aldosterone system encoding genes. METHODS: One-hundred hypertensive patients with target-organ damaging (2nd stage), moderate, high or very high cardiovascular risk were involved in the case-control study. Mean age was 59.87±8.02 y...
Source: Endocrine Regulations - Category: Endocrinology Tags: Endocr Regul Source Type: research
Abstract PURPOSE: There are roughly 30 million Americans diagnosed with diabetes mellitus (DM), with nearly 95% of these cases being type 2 (T2)-DM. The American Diabetes Association continues to recommend metformin as the first-line initial treatment of T2DM, in combination with lifestyle modifications; yet, many require multiple therapies to achieve adequate glycemic control. In patients with atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, adding a glucagon-like peptide 1 receptor agonist is a preferred treatment option; however, many patients are apprehensive about injecting me...
Source: Clinical Therapeutics - Category: Drugs & Pharmacology Authors: Tags: Clin Ther Source Type: research
Conditions:   Type 2 Diabetes Mellitus;   Chronic Kidney Diseases Interventions:   Drug: Cotadutide 100 micrograms;   Drug: Cotadutide 300 micrograms;   Drug: Cotadutide 600 micrograms;   Drug: Semaglutide;   Drug: Placebo Sponsor:   AstraZeneca Not yet recruiting
Source: - Category: Research Source Type: clinical trials
More News: Cardiology | Chronic Kidney Disease | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Heart | Sodium | Urology & Nephrology